샘플 요청 목록

 카트 문의
시장보고서
상품코드
1798941

세계의 간암 치료제 시장

Liver Cancer Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 287 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

간암 치료제 세계 시장은 2030년까지 94억 달러에 달할 전망

2024년에 36억 달러로 추정되는 간암 치료제 세계 시장은 2024-2030년 분석 기간 동안 17.7%의 CAGR로 성장하여 2030년에는 94억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 간세포암은 CAGR 15.7%를 기록하며 분석 기간 종료시에는 33억 달러에 달할 것으로 예측됩니다. 담관암 부문의 성장률은 분석 기간 동안 CAGR 20.2%로 추정됩니다.

미국 시장은 9억 6,790만 달러로 추정, 중국은 CAGR 23.0%로 성장할 것으로 예측

미국의 간암 치료제 시장은 2024년에 9억 6,790만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 21억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 23.0%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 13.3%와 15.8%로 예측됩니다. 유럽에서는 독일이 CAGR 약 14.0%로 성장할 것으로 예측됩니다.

세계의 간암 치료제 시장 - 주요 동향과 촉진요인 정리

간암 치료 환경이 빠르게 변화하는 이유는 무엇일까?

간암, 특히 간세포암(HCC)은 전 세계적으로 가장 공격적이고 치명적인 악성 종양 중 하나이며, 만성 간염 감염, 알코올 유발성 간경변증, 그리고 최근에는 비알코올성 지방간염(NASH)으로 인해 예후가 현저히 나빠지고 이환율이 상승하고 있습니다. 간암 치료제를 둘러싼 환경은 단독요법에서 병용요법 및 개별화 치료 전략으로 패러다임이 변화하고 있습니다. 역사적으로 소라페닙이 지배적이었던 이 시장은 새로운 승인과 파이프라인 후보물질의 물결이 밀려들면서 임상 진료의 판도를 재편하고 있습니다. 분자 프로파일링, 바이오마커 식별, 실시간 질병 모니터링의 중요성이 강조되면서 표적 치료제 및 면역관문억제제로의 전환은 간암 치료에 대한 보다 개인화된 접근을 가능하게 하고 있습니다.

규제 당국이 획기적인 치료제의 심사 일정을 앞당기는 가운데, 아테졸리주맙과 니볼루맙과 같은 면역항암제, 특히 베바시주맙과 같은 혈관 신생 억제제와의 병용요법이 인기를 끌고 있습니다. 이 이중 접근법은 종양의 면역 회피와 혈관 증식을 모두 해결하도록 설계되어 생존 이익과 무악화 결과를 개선하는 데 도움이 될 수 있습니다. 동반진단, 순환 종양 DNA(ctDNA) 분석, 유전체 시퀀싱 플랫폼에 힘입어 암 전문의가 개별 종양 시그니처에 따라 효과적으로 치료법을 맞춤화할 수 있게 되면서 정밀의료가 치료 의사결정의 중심에 서고 있습니다.

기술 발전과 치료 방법은 환자의 결과를 어떻게 변화시키고 있는가?

중재적 종양학 및 분자진단 분야의 기술 발전은 간암 치료의 치료 정확도를 결정적으로 높이고 있습니다. 경동맥화학색전술(TACE), 고주파열소작술(RFA), 선택적 내시경적 방사선치료(SIRT)와 같은 영상유도요법은 중기 간세포암의 치료와 전신요법이 금기인 경우에 매우 중요한 역할을 하고 있습니다. 한편, 로봇 보조 간 수술, 3D 간 모델링, 증강현실 시스템은 절제 가능성 평가와 수술 성적을 향상시키고 있습니다. 이러한 치료법은 조기, 절제불능, 재발 환자를 대상으로 한 다제 병용요법에서 전신요법과 통합되고 있습니다.

차세대 염기서열분석(NGS)과 다분석 액체 생검의 등장으로 종양 전문의들은 TP53, CTNNB1, TERT 등 예후와 치료에 중요한 의미를 갖는 유전자의 변이를 검출할 수 있게 되었습니다. 동시에 임상 연구는 Wnt/β&-카테닌, PI3K/ACT/mTOR, FGFR4 등 종양의 증식과 저항성을 촉진하는 분자 경로를 규명하고 표적으로 삼는 데 집중하고 있습니다. 소라페닙과 렌바티닙 이외의 표적 키나아제 억제제(레고라페닙, 카보잔티닙, 람시루맙 등)가 치료 저항성에서 사용되어 2차 및 3차 치료의 선택의 폭이 넓어지고 있습니다.

유전자 치료, 종양침윤림프구(TIL) 치료, 이중특이성항체는 간암 치료의 개별화를 더욱 앞당길 것으로 기대되는 미래형 개발입니다. 나노입자 캐리어, 리포솜 시스템, 간을 표적으로 하는 프로드러그 등 약물전달 기전의 혁신도 전신 독성을 최소화하면서 생체 이용률을 향상시키고 있습니다. 이러한 기술적, 치료적 발전과 함께 생존에 대한 기대치가 재조정되면서 간세포암 치료의 새로운 표준이 확립되고 있습니다.

간암 치료제 도입이 가속화되고 있는 시장과 부문은?

전 세계 간암의 부담은 동아시아와 사하라 이남 아프리카에 편중되어 있으며, 중국에서만 전 세계 간세포암 발생의 50% 이상을 차지하고 있습니다. 그 결과, 아시아태평양은 간암 치료제의 가장 크고 역동적인 시장으로, 높은 유병률, 정부의 검진 프로그램, 빠르게 확대되고 있는 암 치료제에 대한 접근성이 그 원동력이 되고 있습니다. 일본과 한국도 강력한 국가 암 등록, 높은 진단 인식, 정밀의료와 분자진단에 초점을 맞춘 성숙한 바이오의약품 산업으로 인해 중요한 시장으로 부상하고 있습니다.

북미와 유럽은 강력한 상환 제도, 선진적인 종양학 인프라, 탄탄한 임상시험 파이프라인의 혜택을 누리고 있으며, 그 뒤를 잇고 있습니다. 미국 시장의 특징은 면역관문억제제와 분자 유도 치료제의 높은 보급률, FDA의 우호적인 승인과 고가의 생물학적 제제에 대한 지불자 부담으로 뒷받침되고 있다는 점입니다. 유럽 국가들, 특히 독일과 영국은 조기 발견 프로그램과 간질환 인식 개선 캠페인에 투자하여 말기 증상의 발현을 억제하고 있습니다. 이러한 선진 지역에서는 원격 모니터링과 치료 순응도를 위한 디지털 헬스 플랫폼의 구축으로 치료의 연속성과 추적 관찰이 더욱 강화되고 있습니다.

반면, 라틴아메리카, 중동, 동남아시아 일부 지역에서는 진단 지연, 단편적인 의료 시스템, 최신 치료제에 대한 접근성 제한 등으로 인해 아직은 진단이 제대로 이루어지지 않고 있는 실정입니다. 그러나 국제 NGO, 민관 파트너십, WHO의 B형 및 C형 간염 퇴치를 위한 노력으로 조기 개입과 치료 접근성 개선이 점차 실현되고 있습니다. 제약사들도 이러한 비용에 민감한 지역에 침투하기 위해 차별화된 가격 책정, 라이선싱 계약, 현지 생산 전략을 추구하고 있습니다. 또한, 신흥 시장에서 간 이식 프로그램이 확대됨에 따라 더 많은 환자 집단이 치료 또는 완화 치료 프로토콜의 대상이 되고 있습니다.

세계 간암 치료제 시장의 성장 원동력은?

세계 간암 치료제 시장의 성장은 대사증후군, 바이러스성 간염, 알코올 남용 증가로 인한 간암 발생률 증가, 병용요법 및 면역종양학적 접근으로의 임상적 변화 등 여러 요인에 의해 주도되고 있습니다. 인구 고령화, 좌식 생활습관, 식습관 변화로 인해 비바이러스성 간세포암의 주요 위험요인인 지방간 질환과 NASH가 급증하고 있습니다. 이러한 역학적 변화로 인해 비경화성 간암의 병태생리에 대응하는 맞춤형 약물 개발에 대한 수요가 발생하고 있습니다.

임상 혁신은 주요 성장 촉매제입니다. 표적 치료제, 체크포인트 억제제, 혈관신생억제제(종종 병용)의 무기 확대는 치료의 전망을 크게 넓히고 있습니다. 규제 당국의 조기 승인, 희귀질환 치료제 지정, 접근성 확대 프로그램 등을 통해 신약의 상업적 이용이 더욱 가속화되고 있습니다. 또한, 바이오마커 기반 약물 개발 및 종양 미세환경 연구에 대한 투자가 확대되고 있으며, 맞춤형 백신, CAR-T 치료제, RNA 기반 치료제 등 새로운 치료의 가능성이 생겨나고 있습니다.

경제적, 정책적 인센티브가 이러한 기세를 더욱 강화시키고 있습니다. 고부담 국가 정부는 특히 B형 간염을 대상으로 전국적인 간암 검진 및 백신 접종 프로그램을 시행하고 있습니다. 제약기업들은 합작투자, 임상시험 협력, 현지 R&D 허브를 통해 아시아태평양에서 입지를 확대하고 있습니다. AI를 활용한 간 영상 판독부터 모바일 기반 환자 참여 플랫폼에 이르기까지 디지털 헬스 기술의 통합은 조기 진단과 치료 과정에서의 환자 유지율 향상에 기여하고 있습니다. 이러한 의료, 기술, 사회적, 정치적 촉진요인이 결합하여 간암 치료제 시장의 견조한 성장을 견인하고 있습니다.

부문

유형(간세포암, 담관암, 간아종, 기타 유형), 테라피(표적요법, 방사선 치료, 면역요법, 화학요법)

조사 대상 기업 사례

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • BeiGene Ltd.
  • Bristol-Myers Squibb Company
  • CStone Pharmaceuticals
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • H3 Biomedicine Inc.
  • Innovent Biologics, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계 고유의 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.09.03

Global Liver Cancer Therapeutics Market to Reach US$9.4 Billion by 2030

The global market for Liver Cancer Therapeutics estimated at US$3.6 Billion in the year 2024, is expected to reach US$9.4 Billion by 2030, growing at a CAGR of 17.7% over the analysis period 2024-2030. Hepatocellular Carcinoma, one of the segments analyzed in the report, is expected to record a 15.7% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Cholangio Carcinoma segment is estimated at 20.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$967.9 Million While China is Forecast to Grow at 23.0% CAGR

The Liver Cancer Therapeutics market in the U.S. is estimated at US$967.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 23.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.3% and 15.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.0% CAGR.

Global Liver Cancer Therapeutics Market - Key Trends & Drivers Summarized

Why Is the Therapeutic Landscape for Liver Cancer Rapidly Transforming?

Liver cancer, particularly hepatocellular carcinoma (HCC), represents one of the most aggressive and deadly malignancies globally, with a notably poor prognosis and rising incidence rates driven by chronic hepatitis infections, alcohol-induced cirrhosis, and increasingly, non-alcoholic steatohepatitis (NASH). The transformation of the liver cancer therapeutics landscape is being fueled by paradigm shifts from mono-therapies toward combination regimens and personalized treatment strategies. Historically dominated by sorafenib, the market has seen a wave of new approvals and pipeline candidates that are reshaping clinical practice. The shift to targeted therapies and immune checkpoint inhibitors is enabling a more tailored approach to treating liver cancer, reflecting a growing emphasis on molecular profiling, biomarker identification, and real-time disease monitoring.

With regulatory bodies accelerating review timelines for breakthrough therapies, a growing number of immuno-oncology drugs such as atezolizumab and nivolumab have gained traction, especially in combination with anti-angiogenic agents like bevacizumab. This dual approach is designed to address both tumor immune evasion and vascular proliferation, offering survival benefits and enhanced progression-free outcomes. Precision medicine is becoming central to treatment decision-making, supported by companion diagnostics, circulating tumor DNA (ctDNA) assays, and genomic sequencing platforms that enable oncologists to match therapies to individual tumor signatures more effectively.

How Are Technological Advances and Treatment Modalities Reframing Patient Outcomes?

Technological advancement in interventional oncology and molecular diagnostics is critically enhancing therapeutic precision in liver cancer care. Image-guided therapies such as transarterial chemoembolization (TACE), radiofrequency ablation (RFA), and selective internal radiation therapy (SIRT) continue to play pivotal roles in treating intermediate-stage HCC or when systemic therapy is contraindicated. Meanwhile, robotic-assisted liver surgery, 3D liver modeling, and augmented reality systems are improving resectability assessment and surgical outcomes. These interventions are being increasingly integrated with systemic regimens in multimodal strategies that target early-stage, unresectable, and recurrent cases.

The rise of next-generation sequencing (NGS) and multi-analyte liquid biopsies has allowed oncologists to detect mutations in genes such as TP53, CTNNB1, and TERT, which have prognostic and therapeutic significance. Concurrently, clinical research is focused on identifying and targeting molecular pathways such as Wnt/β-catenin, PI3K/AKT/mTOR, and FGFR4 that drive tumor growth and resistance. Targeted kinase inhibitors beyond sorafenib and lenvatinib-such as regorafenib, cabozantinib, and ramucirumab-are being deployed in treatment-refractory settings, enhancing second- and third-line therapy options.

Gene therapy, tumor-infiltrating lymphocyte (TIL) therapies, and bispecific antibodies represent future-forward developments that are expected to further personalize liver cancer treatment. Innovations in drug delivery mechanisms-including nanoparticle carriers, liposomal systems, and liver-targeted prodrugs-are also improving bioavailability while minimizing systemic toxicity. Together, these technological and therapeutic advances are recalibrating survival expectations and establishing new standards in hepatocellular carcinoma care.

Which Markets and Segments Are Accelerating Liver Cancer Therapeutics Adoption?

The global burden of liver cancer is disproportionately concentrated in East Asia and sub-Saharan Africa, with China alone accounting for over 50% of global HCC cases. Consequently, Asia-Pacific is the largest and most dynamic market for liver cancer therapeutics, driven by high prevalence, government screening programs, and rapidly expanding oncology drug access. Japan and South Korea are also significant due to strong national cancer registries, high diagnostic awareness, and a mature biopharmaceutical industry focused on precision medicine and molecular diagnostics.

North America and Europe follow closely, benefitting from strong reimbursement structures, advanced oncology infrastructure, and robust clinical trial pipelines. The U.S. market is characterized by high adoption of immune checkpoint inhibitors and molecularly guided therapies, supported by favorable FDA approvals and payer coverage for high-cost biologics. European countries, particularly Germany and the UK, are investing in early detection programs and liver disease awareness campaigns to curb late-stage presentations. The rollout of digital health platforms for remote monitoring and therapy adherence is further enhancing treatment continuity and follow-up care in these developed regions.

In contrast, Latin America, the Middle East, and parts of Southeast Asia present underpenetrated markets where late diagnosis, fragmented health systems, and limited access to modern therapeutics persist. However, international NGOs, public-private partnerships, and WHO initiatives aimed at hepatitis B and C elimination are slowly enabling earlier intervention and improved access to treatment. Pharmaceutical companies are also pursuing differential pricing, licensing agreements, and local manufacturing strategies to penetrate these cost-sensitive geographies. Additionally, with liver transplant programs expanding in emerging markets, a larger cohort of patients are now becoming eligible for curative or palliative therapeutic protocols.

What Is Fueling Growth in the Liver Cancer Therapeutics Market Globally?

The growth in the global liver cancer therapeutics market is driven by several factors, including the increasing incidence of liver cancer due to rising metabolic syndrome, viral hepatitis, and alcohol abuse, as well as the clinical shift toward combination therapies and immuno-oncology approaches. Aging populations, sedentary lifestyles, and dietary changes have led to a surge in fatty liver disease and NASH, which are major risk factors for non-viral HCC. This epidemiological shift is creating demand for tailored drug development that addresses non-cirrhotic liver cancer pathophysiology.

Clinical innovation is a major growth catalyst. The expanding armamentarium of targeted therapies, checkpoint inhibitors, and angiogenesis blockers-often used in combination-has significantly broadened the treatment landscape. Regulatory fast-tracking, orphan drug designations, and expanded access programs are further accelerating the commercial availability of novel agents. Moreover, growing investments in biomarker-driven drug development and tumor microenvironment research are generating new therapeutic possibilities, including personalized vaccines, CAR-T therapies, and RNA-based therapeutics.

Economic and policy incentives are reinforcing this momentum. Governments in high-burden countries are implementing national liver cancer screening and vaccination programs, especially for hepatitis B. Pharmaceutical companies are expanding their presence in Asia-Pacific through joint ventures, clinical trial collaborations, and local R&D hubs. The increasing integration of digital health technologies-ranging from AI-based liver imaging interpretation to mobile-based patient engagement platforms-is also contributing to early diagnosis and improved patient retention in care pathways. Together, these medical, technological, and socio-political drivers are propelling robust growth in the liver cancer therapeutics market.

SCOPE OF STUDY:

The report analyzes the Liver Cancer Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, Other Types); Therapy (Targeted Therapy, Radiation Therapy, Immunotherapy, Chemotherapy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • BeiGene Ltd.
  • Bristol-Myers Squibb Company
  • CStone Pharmaceuticals
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • H3 Biomedicine Inc.
  • Innovent Biologics, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Liver Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Burden of Hepatocellular Carcinoma Throws the Spotlight on Targeted Therapies
    • Expansion of Immuno-Oncology Research Pipelines Propels Growth in Checkpoint Inhibitors
    • Increased Adoption of Systemic Therapies Drives Demand for Advanced First-Line Treatment Options
    • FDA Fast-Track Approvals and Orphan Drug Designations Accelerate Market Entry for Novel Therapies
    • Growing Integration of Biomarker-Driven Approaches Expands Addressable Patient Populations
    • Clinical Advancements in Combination Therapies Strengthen Business Case for Multi-Target Regimens
    • Rise in Hepatitis B and C Prevalence Spurs Demand for Early-Stage Therapeutic Interventions
    • Expansion of Interventional Oncology Techniques Spurs Adoption of Drug-Eluting Bead Technologies
    • Increased Investment in Radiopharmaceuticals Drives Pipeline Activity in Liver Cancer Segment
    • Growing Emphasis on Genomic and Molecular Profiling Enhances Precision in Therapy Selection
    • Shift Toward Personalized Medicine Strategies Drives Interest in Companion Diagnostics
    • Rising Incidence in Asia-Pacific and Sub-Saharan Africa Expands Geographically Diverse Market Opportunities
    • Collaborations with Academic Institutions Propel Innovation in Liver Tumor Immunotherapy
    • Post-Transplant Recurrence Risk Management Sustains Demand for Adjuvant Therapeutic Options
    • Pharmaceutical R&D Consolidation Spurs Licensing and Co-Development of Liver Cancer Assets
    • Regulatory Revisions for Accelerated Approvals Drive Pipeline Commercialization
    • Increase in Health Awareness Campaigns Improves Early Diagnosis and Therapeutic Uptake
    • Advances in Liquid Biopsy Techniques Strengthen Non-Invasive Treatment Monitoring
    • Reimbursement Expansion in Developed Markets Enhances Access to Premium Therapies
    • Challenges in Treatment Response Variability Reinforce Need for Adaptive Therapy Models
    • Expansion of Cell-Based and mRNA Therapies Generates Long-Term Disruption Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Liver Cancer Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Liver Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Liver Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hepatocellular Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hepatocellular Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hepatocellular Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cholangio Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cholangio Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Cholangio Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hepatoblastoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hepatoblastoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hepatoblastoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • JAPAN
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • CHINA
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • EUROPE
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Liver Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Liver Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • FRANCE
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • GERMANY
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Liver Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Liver Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • INDIA
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Liver Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Liver Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Liver Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Liver Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030
  • AFRICA
    • Liver Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Liver Cancer Therapeutics by Type - Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Liver Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Other Types for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Liver Cancer Therapeutics by Therapy - Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Liver Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Radiation Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제